Conference Reports for NATAP

66th Annual Meeting of the American Association for the Study of Liver Diseases Boston, MA Nov 13-17 2015 Back

BMS at AASLD       AASLD: Summary from AASLD 2015 for Hepatitis C Beyond 95% SVR cure rates: still room for improvement? Jurgen K. Rockstroh M.D., Professor of Medicine University of Bonn, Germany   Daclatasvir (Daklinza) FDA Product Information - (12/21/15)   Bristol-Myers Squibb to Present Data from Multiple Studies of Difficult-to-Treat Chronic Hepatitis C Patients at AASLD - (10/21/15)   AASLD: All-Oral Treatment With Daclatasvir Plus Sofosbuvir Plus Ribavirin for 12 or 16 Weeks in HCV Genotype 3-Infected Patients With Advanced Fibrosis or Cirrhosis: The ALLY-3+ Phase 3 Study - (11/23/15)   AASLD: Daclatasvir Plus Sofosbuvir With or Without Ribavirin in Patients With HCV Genotype 3 Infection: Interim Analysis of a French Multicenter Compassionate Use Program - (12/01/15)   AASLD: Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV in Patients Coinfected With HIV: Interim Results of a Multicenter European Compassionate Use Program - (11/18/15) GT1/3/4   EASL: Daclatasvir Plus Sofosbuvir for Treatment of HCV Genotypes 1-4 in HIV-HCV Coinfection: The ALLY-2 Study - (04/28/15)   AASLD: Daclatasvir and Asunaprevir in Non-Japanese Asian Patients with Chronic HCV Genotype 1b Infection who are Ineligible for or Intolerant to Interferon-alfa Therapies with or without Ribavirin: Phase 3 SVR12 Interim Results - (11/23/15)   AASLD: Daclatasvir Plus Sofosbuvir With or Without Ribavirin for the Treatment of Chronic HCV in Patients Coinfected With HIV: Interim Results of a Multicenter European Compassionate Use Program (advanced liver disease) - (12/03/15) Gt1/3/4   AASLD: Improvement in Liver Disease Parameters Following Treatment with Daclatasvir + Sofosbuvir and Ribavirin in Patients With Chronic HCV Infection and Advanced Cirrhosis - (12/03/15)   AASLD: Daclatasvir and Sofosbuvir in Patients with Recurrent HCV Following Liver Transplantation with Advanced Fibrosis or Cirrhosis: United States Multicenter Treatment Protocol - (12/01/15)   AASLD: Daclatasvir in Combination With Sofosbuvir With Or Without Ribavirin Is Safe and Efficacious in Liver Transplant Recipients With HCV Recurrence: Interim Results of a European Multicenter Compassionate Use Program - (12/01/15)   AASLD: Integrated Safety Analysis of Daclatasvir Plus Sofosbuvir, With or Without Ribavirin, in Patients With HCV Genotype 3 Infection - (12/03/15)   AASLD: Cost-effectiveness of Combination Daclatasvir-Sofosbuvirfor Genotype 3 Chronic Hepatitis C Infection in the United States - (12/03/15)   AASLD: An Integrated Safety Analysis of Daclatasvir + Sofosbuvir, With or Without Ribavirin, in Patients With Chronic HCV Infection - (12/03/15)   AASLD: Impact of Daclatasvir-Sofosbuvir Combination Treatment on Avoided Medical Events and Costs in Patients Infected with Genotype 3 Hepatitis C Virus - (12/03/15)   AASLD: Short-Duration Therapy With Daclatasvir/Asunaprevir/Beclabuvir Fixed-Dose Combination Plus Sofosbuvir in Patients With Chronic Hepatitis C Genotype 1 (FOURward Study) - (12/04/15)   AASLD: Daclatasvir Exposure Does Not Explain Lower Sustained Virologic Response Rates in Cirrhotic Patients With HCV Genotype 3 Following 12 Weeks of Daclatasvir Plus Sofosbuvir Treatment - (12/04/15)   AASLD: Daclatasvir Exposure Alone Does Not Explain HCV Relapse in HIV-HCV Coinfected Patients Receiving Daclatasvir Plus Sofosbuvir with Ritonavir-Boosted Darunavir in the ALLY-2 Study - (11/18/15)   More Hep C Articles...